Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Capital Expenditures (2019 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Capital Expenditures for 7 consecutive years, with $333000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 69.78% to $333000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Dec 2025, down 38.61% year-over-year, with the annual reading at $2.4 million for FY2025, 38.61% down from the prior year.
  • Capital Expenditures hit $333000.0 in Q4 2025 for IDEAYA Biosciences, up from $42000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $2.1 million in Q2 2024 to a low of -$927000.0 in Q3 2023.
  • Historically, Capital Expenditures has averaged $655736.8 across 5 years, with a median of $550000.0 in 2022.
  • Biggest five-year swings in Capital Expenditures: skyrocketed 1060.61% in 2021 and later tumbled 184.2% in 2023.
  • Year by year, Capital Expenditures stood at $605000.0 in 2021, then skyrocketed by 81.98% to $1.1 million in 2022, then tumbled by 86.65% to $147000.0 in 2023, then soared by 649.66% to $1.1 million in 2024, then plummeted by 69.78% to $333000.0 in 2025.
  • Business Quant data shows Capital Expenditures for IDYA at $333000.0 in Q4 2025, $42000.0 in Q3 2025, and $1.3 million in Q2 2025.